Douglas Miehm
Stock Analyst at RBC Capital
(1.09)
# 3,420
Out of 4,818 analysts
47
Total ratings
29.73%
Success rate
-12.82%
Average return
Main Sectors:
Stocks Rated by Douglas Miehm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLCO Bausch + Lomb | Maintains: Outperform | $18 → $17 | $12.78 | +33.07% | 13 | Apr 4, 2025 | |
| ONCY Oncolytics Biotech | Maintains: Outperform | $6 → $5 | $0.56 | +791.42% | 1 | Mar 10, 2025 | |
| BHC Bausch Health Companies | Maintains: Sector Perform | $11 → $10 | $5.17 | +93.42% | 19 | Jan 30, 2025 | |
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $141 → $143 | $106.00 | +34.91% | 5 | Dec 11, 2024 | |
| AUPH Aurinia Pharmaceuticals | Maintains: Outperform | $13 → $8 | $8.10 | -1.17% | 9 | Feb 16, 2024 |
Bausch + Lomb
Apr 4, 2025
Maintains: Outperform
Price Target: $18 → $17
Current: $12.78
Upside: +33.07%
Oncolytics Biotech
Mar 10, 2025
Maintains: Outperform
Price Target: $6 → $5
Current: $0.56
Upside: +791.42%
Bausch Health Companies
Jan 30, 2025
Maintains: Sector Perform
Price Target: $11 → $10
Current: $5.17
Upside: +93.42%
Ligand Pharmaceuticals
Dec 11, 2024
Maintains: Outperform
Price Target: $141 → $143
Current: $106.00
Upside: +34.91%
Aurinia Pharmaceuticals
Feb 16, 2024
Maintains: Outperform
Price Target: $13 → $8
Current: $8.10
Upside: -1.17%